HIV mutation literature information.


  Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
 PMID: 26651266       2016       AIDS research and human retroviruses
Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing V90I, A98G, L100I/V, K101H/Q/T, K103R/S, V106A/I, V108I, E138S, V179D/E/F/I/T, Y181F/G/S, Y188F, V189I, G190A/C/E/Q/S/T/V, and M230V


  Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
 PMID: 27120449       2016       PloS one
Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,


  Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
 PMID: 25849352       2015       PLoS medicine
Result: Nevirapine and efavirenz resistance were predicted in about 1% and 0.5% of virus samples without NNRTI SDRMs as a result of several minimally polymorphic (e.g., A98G, V108I, and V179D) and rare nonpolymorphic (e.g., E138K, G190Q, F227C, and K238T) NNRTI-resistance mutations.


  HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
 PMID: 26717411       2015       PloS one
Figure: Major NNRTI-associated DRMs (HIVDB score >=60) included: L100I, K101P, K103N/S, V106A/M, Y181C/I/V, Y188L/H/C, G190A/S/E/Q, and M230L.


  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
 PMID: 23934770       2014       The Journal of antimicrobial chemotherapy
Abstract: RESULTS: Sixteen mutations at 10 positions were significantly associated with the greatest contribution to reduced phenotypic susceptibility (>=10-fold) to one or more NNRTIs, including: 14 mutations at six positions for nevirapine (K101P, K103N/S, V106A/M, Y181C/I/V, Y188C/L and G190A/E/Q/S); 10 mutations at six positions for efavirenz (L100I, K101P, K103N, V106M, Y188C/L and G190A/E/Q/S); 5 mutations at four positions for etravirine ( PMID: 23840622       2013       PloS one
Method: Different RT mutations at the same residue were pooled, including the NRTI-resistance mutations D67NG, K70EGQ, L74VI, M184VI, T215YF, K219QE and the NNRTI-resistance mutations K101EH, K103NS, Y188LCH, and G190ASEQ.
Method: The following non-polymorphic ARV-selected mutations were classified as drug resistance mutations (DRM): (i) the NRTI resistance mutations M41L,  PMID: 24015311       2013       PloS one
Result: The most frequently detected mutations were: M184I/V (92.3%), Y181C/I/V (47.1%), T215I/C/F/N/S (38.8%), D67E/G/N (37.3%), K103N/R/S (33.9%), and G190A/Q/S (32.5%).


  Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.
 PMID: 22984494       2012       PloS one
Discussion: Thus far, about 32 NVP-resistance associated mutations in 17 positions, including 15 major NVP-resistant mutations at 5 positions (K103NST, V106AM, Y181CIV, Y188LHC, G190ASEQ), have been summarized in HIV drug resistance database of Stanford University.


  Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.
 PMID: 21799767       2011       PloS one
Abstract: Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q.
Result: Figure 1B shows that the mean DeltaCt for NVP seen in 83 WT isolates was 7.42+-3.18 (range 0.235-15.9) compared to a mean DeltaCt value of 0.484+-0.963 (range -1.85-2.15) seen in 28 NV
Table: G190A/Q


  Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
 PMID: 20462946       2010       The Journal of antimicrobial chemotherapy
Method: These mutations included: (i) 46 non-polymorphic NNRTI-selected mutations at 28 positions (I94L, A98G, L100I, K101E/H/N/P, K102N, K103H/N/S/T, S105T, V106A/M, E138Q, T139R, I178F, V179F, Y181C/I/V, Y188C/H/L, G190A/C/E/Q/S, H221C/Y, K223T,



   Filtrator